Asthmatic crisis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Asthmatic crisis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Long-term safety and effectiveness study of verekitug injections in adults with severe asthma who completed the VALIANT trial https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-verekitug-injections-in-adults-with-severe-asthma-who-completed-the-valiant-trial/ Wed, 29 Apr 2026 15:06:59 +0000 https://clinicaltrials.eu/trial/long-term-safety-and-effectiveness-study-of-verekitug-injections-in-adults-with-severe-asthma-who-completed-the-valiant-trial/ This study focuses on people with severe asthma, a condition where breathing becomes difficult due to inflammation and narrowing of the airways. The study will test a medication called Verekitug (also known as UPB-101), which is given as an injection under the skin. This medicine is a type of monoclonal antibody, which is a protein designed to target specific substances in the body that contribute to asthma symptoms.

The purpose of this research is to evaluate the safety and effectiveness of long-term treatment with Verekitug in adults who have previously participated in another study called VALIANT. During the study, participants will receive either Verekitug or a placebo as an injection under the skin for approximately 60 weeks. The study will monitor how well participants’ asthma is controlled and how their breathing functions over time.

Throughout the study, participants will have regular check-ups that include breathing tests, blood samples, and questionnaires about their asthma symptoms. The study will track how often participants experience asthma flare-ups that require treatment with steroids. Blood samples will be collected to measure the amount of medicine in the body and to check for the body’s immune response to the treatment.

]]> Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma https://clinicaltrials.eu/trial/study-on-the-effects-of-verekitug-upb-101-for-adults-with-severe-asthma/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-verekitug-upb-101-for-adults-with-severe-asthma/ This clinical trial is focused on studying Severe Asthma, a condition where the airways in the lungs become inflamed and narrowed, making it difficult to breathe. The study will evaluate a treatment called Verekitug (UPB-101), which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific targets in the body. In this case, Verekitug (UPB-101) targets a protein involved in asthma symptoms. The trial will compare the effects of this treatment to a placebo, which is a substance with no active treatment.

The purpose of the study is to assess how Verekitug (UPB-101) affects asthma flare-ups, also known as exacerbations, in adults with severe asthma. Participants in the study will receive either the active treatment or a placebo through an injection under the skin, known as a subcutaneous injection. The study will last for about 60 weeks, during which participants will have regular check-ups to monitor their asthma symptoms and overall health.

Throughout the study, researchers will collect information on how often asthma exacerbations occur and any changes in lung function. This will help determine the safety and effectiveness of Verekitug (UPB-101) as a potential treatment for severe asthma. Participants will be closely monitored to ensure their safety and well-being during the trial.

]]>